{"id":209650,"name":"OYE THEREPEUTICS","slug":"oye-therepeutics","state":"IN","country":"United States of America","description":"Pharmaceutical, development stage, company","totalSpending":540000,"filings":21,"yearlySpending":[{"year":2021,"income":100000},{"year":2022,"income":120000},{"year":2023,"income":120000},{"year":2024,"income":120000},{"year":2025,"income":80000}],"issues":[{"code":"HCR","display":"Health Issues"}],"firms":["BELL & LINDSAY, INC."],"lobbyists":["MARK LINDSAY","ANTHONY FIMOGNARI","ERIK DELL"],"govEntities":["Defense, Dept of (DOD)","HOUSE OF REPRESENTATIVES","Office of Management & Budget (OMB)","Office of Natl Drug Control Policy (NDCP)","Office of Science & Technology Policy (OSTP)","SENATE","Executive Office of the President (EOP)","Food & Drug Administration (FDA)","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Government affairs and communication services","General Consulting","General Consulting and informing federal agencies and Congress on the research that OYE Therapeutics is currently doing.","General Consulting and informing federal agencies and Congress on the research that OYE Therapeutics is currently doing.","General Consulting and informing federal agencies and Congress on the research that OYE Therapeutics is currently doing."]}